Keytruda qlex 395 MG-4800 unit 2.4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMEC9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,901
Award facts
- Contract value 100% obligated
- $34,900.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $34.9K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 395 mg-4800 unit 2.4 mL Keytruda (pembrolizumab), an oncology therapeutic. This firm fixed-price delivery order, issued December 29, 2025, with an ultimate completion date of December 30, 2025, carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The award was funded by the Defense Logistics Agency and represents a point-in-time pharmaceutical supply requirement for military healthcare operations.
This delivery order operates under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency designated SPE2DR, awarded November 13, 2025, under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The parent IDC carries a $499.9B ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor within the broader $30.3B PPV-G GEN V acquisition strategy. The IDC authorizes the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense healthcare facilities worldwide, with DMS Pharmaceutical Group's established performance on numerous recent delivery orders demonstrating its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FMEC9?
SPE2DR26FMEC9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 29, 2025.
How much is contract SPE2DR26FMEC9 worth?
The government has obligated $34,901 on SPE2DR26FMEC9.
Is contract SPE2DR26FMEC9 an order under another contract?
Yes. SPE2DR26FMEC9 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMEC9 competed?
The extent of competition for SPE2DR26FMEC9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award